Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

Original languageEnglish
Article number2200701
JournalEurosurveillance
Volume27
Issue number39
DOIs
StatePublished - Sep 2022
Externally publishedYes

Bibliographical note

Funding Information:
GRY reports institutional grant funding of studies not related to the current study from Pfizer, consulting/honoraria from Teva, MSD, Astrazeneca, Pfizer and Moderna. NB and YL report institutional grants from Pfizer. All other authors report no conflicts of interest.

Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Fingerprint

Dive into the research topics of 'Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022'. Together they form a unique fingerprint.

Cite this